Histone Deacetylase Inhibitors (HDIs) with antineoplastic and antiosteolytic properties

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/519239

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Metastatic bone disease is very common in patients with many forms of solid tumours. Our approach to use Histone Deacetylase Inhibitors (HDIs), to target bone metastases offers an exciting therapeutic potential. Treatment with HDIs will have the potential to suppress cancer-induced bone destruction by integrating the cytotoxic and osteotropic properties that reside within the same compound. Our preclinical data will facilitate the translation of HDIs to clinical trials for bone cancer.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2011

Funding Scheme: NHMRC Project Grants

Funding Amount: $535,333.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Orthopaedics

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Animal Models | Bone Cancer Therapy | Bone Metastasis | Bone metastases | Breast, Prostate Cancer and Multiple Myeloma | Histone Deacetylase Inhibitors | Novel Therapeutics | Osteoclast and Osteoblast function | Osteolysis | Preclinical Animal Models

Related Links